ASTMH 2013

[November 13 – 17, 2013]
American Society of Tropical Medicine and Hygiene, 62nd Annual Meeting
Washington DC, United States



DNDi @ ASTMH 2013 [PDF] DNDi @ ASTMH 2013 – At a glance [PDF]

Thursday, November 14, 2013

POSTER (#LB-2117): SCYX-7158 (AN5568): CNS Exposure Predicted from First-in-Human Clinical Studies Indicates a Single Oral Dose Treatment is Possible for Sterile Cures of Stage 2 Human African Trypanosomiasis

Authors: Stephen Wring,1 Eric Gaukel,1 Robert Jacobs,2 Sanjay Chanda,2 Virginie Gualano,3 Eric Evène,3 Yves Donazzolo,4 Mathilde Latreille,4 Robert Don,5 Charles Mowbray,5 Antoine Tarral5


  • 1. Scynexis Inc, Research Triangle Park, NC, USA
  • 2. Anacor Pharmaceuticals Inc, Palo Alto, CA, USA
  • 3. PhinC Development, Evry, France
  • 4. Eurofins Optimed, Gières, France
  • 5. DNDi, Geneva, Switzerland

Download Poster
SYMPOSIUM (Session #53): Chagas Disease: Recent Advances in Research and Development

  • Organizer: Isabela Ribeiro, Drugs for Neglected Diseases initiative, Geneva, Switzerland
  • Co-Chair: Sergio Sosa-Estani, Instituto Nacional de Parasitología “Dr. Mario Fatala Chaben”, Buenos Aires, Argentina
    • E 1224—results of proof-of-concept clinical trial in patients with chronic indeterminate Chagas disease, Faustino Torrico, Facultad de Medicina de la Universidad Mayor de San Simon, Cochabamba, Bolivia
    • Population-pharmacokinetics of benznidazole in children and adults with Chagas disease, Jaime Altcheh, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina
    • TRAENA – placebo-controlled evaluation of impact of benznidazole treatment on long term disease progression in adults with chronic Chagas disease, Adelina Riarte, Instituto Nacional de Parasitología “Dr. Mario Fatala Chaben”, Buenos Aires, Argentina
    • Advances in biological markers of therapeutic response in Chagas disease, Maria Jesus Pinazo, CRESIB – Barcelona Centre for International Health Research, Barcelona, Spain; Alejandro Schijman, CONICET – INGEBI, Argentina, Buenos Aires, Argentina

Description: Chagas disease ranks among the world’s most neglected diseases. After decades of limited progress, the last few years have witnessed a significant change in the landscape of research and drug development in Chagas disease. The proposed symposium will provide an overview of new data on old compounds, treatment regimens, new drug candidates and biological markers from key experts in the field. The first presentation will provide the announcement of the results of the first clinical trial of E1224, a pro-drug of ravuconazole, in the treatment of Chagas disease in adults with chronic indeterminate Chagas disease. The second presentation will summarize new data on pharmacokinetics and pharmacodynamics of benznidazole in the treatment of adults and children with Chagas disease. The third presentation will describe the results of the TRAENA clinical trial, a placebo-controlled evaluation of the efficacy and safety of benznidazole in adult patients with chronic Chagas disease. This study involves follow-up of patients for approximately 10 years with assessment of long-term disease progression. The fourth and last presentation will provide a review of recent advances in biological markers of therapeutic response.

Advancing Life-Saving R&D Innovations for People Living with Chagas Diseases – The Silent Killer

Organizers/sponsors: DNDi,Sabin Vaccine Institute/National School of Tropical Medicine at Baylor College of Medicine, Doctors Without Borders/Médecins Sans Frontières (MSF), Global Chagas Disease Coalition, Research!America, ASTMH, and PAHO


  • Introduction and video
  • Dr. Peter Hotez, Sabin/NSTM/BCM
  • Dr. Isabela Ribeiro, DNDi
  • Jenny Sanchez and Dr. Rachel Marcus, LaSocha, US Chagas disease patients association
  • Sonia Tarragona, Mundo Sano; representing the Global Chagas Disease Coalition
  • Dr. Luis Gerardo Castellanos, PAHO
  • Panel discussion, moderated by Dr. Estrella Lasry, MSF

Friday, November 15, 2013

  POSTER (#813): Efficacy, Safety, and Population-Pharmacokinetics of the Artesunate-Mefloquine (ASMQ) fixed dose combination versus Artemether-Lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in African children

Authors: Monia Guidi,1,2 Laurent A. Decosterd,2 Thomas Mercier,2 Chantal Csajka,1,2 Kevin Omondi,3 Bernhards Ogutu,3 Gwénaëlle Carn,4 Jean-René Kiechel4


  • 1. School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Switzerland
  • 2. Laboratory and Division of Clinical Pharmacology Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
  • 3. Kenya Medical Research Institute, Kisumu, Kenya
  • 4. Drugs for Neglected Diseases initiative, Geneva, Switzerland

Download Poster

Media contacts (on site):
(North America; English) Oliver Yun: e-mail: / Mobile: +1-646-266-5216
(Latin America; Español/Português) Betina Moura: e-mail: / Mobile: +55 21 8122 2798

ASTMH website